TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program

12 Mar 2019

Trace Histories is a purpose-built distributed ledger solution for ensuring patient safety by 2023 DSCSA deadline.

TraceLink has submitted its interoperable blockchain network solution for the FDA Pilot Project Program under the Drug Supply Chain Security Act (DSCSA). Built on TraceLink’s digital supply network, Trace Histories leverages distributed ledger technology and is designed specifically to help pharmaceutical manufacturers, wholesale distributors, pharmacies, and hospitals securely exchange information and satisfy the 2023 DSCSA requirement.

TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program

“The 275,000+ partners on our end-to-end digital supply network are already validated, which provides companies with a unique opportunity to leverage blockchain technology, while ensuring the safe exchange of data,” said Shabbir Dahod, president and CEO, TraceLink. “By combining our nearly two decades of expertise in standards-based compliance for track and trace in the pharmaceutical supply chain with our deep technical knowledge, we have created Trace Histories, a breakthrough blockchain solution. Trace Histories maintains the pseudonymity of blockchain participants and control of confidential information within each participant’s system by only enabling the disclosure of information necessary to respond to verified trace requests.”

With the unique advantage of leveraging TraceLink's end-to-end digital network and existing base of pre-verified customers and trade partners, Trace Histories is a distributed ledger network that integrates directly into companies’ existing global compliance and serialization infrastructures. The blockchain network solution employs a “gather upon request” approach with permissioned data security, allowing companies to securely share critical and confidential information with authorized partners in an open, interoperable format to meet the final 2023 DSCSA deadline requiring full unit level traceability across the supply chain. Trace Histories was designed from the ground up to be standardized and support interoperability across blockchain networks.

Other participants in TraceLink’s pilot project include pharmaceutical manufacturers, wholesale distributors, major retail pharmacy chains, diversified healthcare organizations, and third-party logistics providers. The pilot project will be guided and managed by TraceLink’s Blockchain Network Innovation Forum.

By 2023, members of the US supply chain will need to have processes and systems in place to meet the DSCSA requirement for an interoperable, electronic tracing of pharmaceutical products at the packaging level. Announced by the FDA last month, the DSCSA Pilot Project Program is a 2019 effort to explore technologies that will enhance the tracing and verification of pharmaceutical products in the US supply chain.

Read More

Related news

Funding to accelerate delivery of Univercells' vaccine portfolio

Funding to accelerate delivery of Univercells' vaccine portfolio

11 Oct 2019

European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.

Read more 
Industrial-scale manufacture of therapeutic exosomes

Industrial-scale manufacture of therapeutic exosomes

10 Oct 2019

Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.

Read more 
Janssen opens new biomanufacturing building in Ireland

Janssen opens new biomanufacturing building in Ireland

8 Oct 2019

Expansion creates 200 new full-time jobs and increases the company’s production capacity by an additional 19,100 m2.

Read more 
BASF and Biomillenia join forces in microbiome research to promote healthy skin

BASF and Biomillenia join forces in microbiome research to promote healthy skin

7 Oct 2019

Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.

Read more 
Allergan expands Refresh eye treatment portfolio

Allergan expands Refresh eye treatment portfolio

7 Oct 2019

A trifecta of relief formulated with HydroCell technology offers new artificial tear options for patients suffering from eye dryness.

Read more 
BASF strengthens biotechnology footprint to enter natural F&F ingredients market

BASF strengthens biotechnology footprint to enter natural F&F ingredients market

3 Oct 2019

Market entrance with biotech-based natural vanillin, valencene and nootkatone.

Read more 
Unidose device approved for Tosymra sumatriptan spray

Unidose device approved for Tosymra sumatriptan spray

3 Oct 2019

Provides migraine sufferers with a convenient, patient-friendly delivery approach.

Read more 
One-stop-platform for plant-based nutraceuticals

One-stop-platform for plant-based nutraceuticals

2 Oct 2019

In 2020, nutra brands will look to ensure they have plant-based options across all product classes with many actively looking to move entire portfolios plant-based.

Read more 
BASF's new bioactive ingredient the wellness elixir for healthy skin

BASF's new bioactive ingredient the wellness elixir for healthy skin

1 Oct 2019

The active ingredient is a 100% natural extract from the chaga mushroom, obtained using an innovative eco-friendly technology: subcritical water extraction.

Read more 
Arctoris secures funding to advance novel robotic drug discovery platform

Arctoris secures funding to advance novel robotic drug discovery platform

1 Oct 2019

Platform will enable scientists and biotechnology entrepreneurs worldwide to make discoveries faster and more efficiently,

Read more